

ART 34 AMDT

CLAIMS:

- 1 1. A stable pharmaceutical composition for oral administration of ACE inhibitor(s)
2 comprising
 - 3 i) a core; coated with a layer of ACE inhibitor(s).
 - 4 ii) a seal coat on the core; and
 - 5 iii) an ACE inhibitor layer which is free of plasticizers and organic solvents.
- 1 2. The composition of claim 1 wherein the ACE inhibitor is selected from the group
2 consisting of ramipril, quinapril, enalapril, spirapril, lisinopril and benazepril.
- 1 3. The composition of claim 1 wherein the layer of ACE inhibitor(s) comprises film
2 forming polymer.
- 1 4. The composition of claim 3 wherein the film forming polymer is selected from the
2 group consisting of hydroxypropylcellulose, hydroxypropylmethylcellulose,
3 hydroxyethylcellulose, ethylcellulose, cellulose acetate, polyvinylpyrrolidone, gelatin,
4 a combination of microcrystalline cellulose and carrageenan, and a combination of
5 polyvinyl alcohol and polyvinylacetate.
- 1 5. The composition of claim 1, wherein the core is a compressed tablet.
- 1 6. The composition of claim 1, wherein the core comprises a sugar sphere or nonpareil
2 seeds.
- 1 7. The composition of claim 5 or 6, wherein compressed tablets, sugar spheres or
2 nonpareil seeds are filled into hard gelatin capsules.
- 1 8. The composition of claim 1, wherein the core is inert.
- 1 9. The composition of claim 1, wherein the core has a pharmaceutically active substance
2 other than the one which is susceptible to degradation by mechanical stress.
- 1 10. The composition of claim 9, wherein the pharmaceutically active substance is
2 selected from the group consisting of hydrochlorothiazide, piretanide, and
3 dihydropyridines

ART 34 AMDT RLL-234WO

- 1 11. The composition of claim 1 wherein the seal coat comprises film forming polymer
- 1 12. The composition of claim 11 wherein the film forming polymer is selected from the
2 group consisting of hydroxypropylcellulose, hydroxypropylmethylcellulose,
3 hydroxyethylcellulose, ethylcellulose, cellulose acetate, polyvinylpyrrolidone, gelatin,
4 a combination of microcrystalline cellulose and carrageenan, and a combination of
5 polyvinyl alcohol and polyvinylacetate.
- 1 13. The composition of claim 1 wherein the ACE inhibitor layer is further surrounded with
2 an outer coat.
- 1 14. A process for the preparation of a stable pharmaceutical composition for oral
2 administration of ACE inhibitor(s) comprising applying a seal coat on a core and
3 disposing a layer of an ACE inhibitor dispersion, suspension which is free of
4 plasticizers and organic solvents onto the coated core.
- 1 15. The process of claim 14, wherein the layer is disposed as a coating dispersion.
- 1 16. The process of claim 15, wherein the coating dispersion is made in aqueous solvent.
- 1 17. The process of claim 14, wherein the dispersion is sprayed on the cores.
- 1 18. A method of treating a disorder selected from the group consisting of hypertension,
2 congestive heart failure, left ventricular dysfunction and diabetic nephropathy, the
3 method comprising administration of a therapeutically effective amount of the
4 pharmaceutical composition of claim 1 to a patient suffering from such a disorder.